Evidence of genetic anticipation in HLRCC

Genetic anticipation describes the phenomenon where symptoms appear at an earlier age or are more severe, or both, in subsequent generations of families with a genetic disease. This phenomenon is commonly seen in neurodegenerative diseases (Trottier et al., 1994), and in some hereditary cancers including breast, ovarian and pancreatic cancer (Dagan and Gershoni-Baruch, 2002, Martinez-Borges et al., 2009, Schneider et al., 2011). A recent study by Wong et al. (2014) suggests that there is genetic anticipation in families with HLRCC.

Following the observation that some of the HLRCC families under their care seemed to be showing genetic anticipation with respect to kidney cancer, the authors decided to systematically investigate whether this is the case. Review of the literature and their case series identified 11 families where at least two generations of a family were affected with renal cell carcinoma (RCC), and where ages of diagnosis and/or death were available.

In all families there was evidence of genetic anticipation. Most of the families carried an FH mutation unique to that family, suggesting that genetic anticipation in HLRCC can be caused by multiple mutations, if not all FH mutations. On average, children were diagnosed with RCC 18.6 years earlier than their affected parent, and grandchildren were diagnosed 36.2 years sooner, suggesting an additive effect in each generation. There was no evidence of genetic anticipation for the uterine symptoms of HLRCC, and skin symptoms were not analysed due to the difficulty in accurately determining when this symptom first appears. In the family that most strongly showed anticipation for RCC, the proband was diagnosed with RCC at the age of 17, his two affected uncles were diagnosed at 34 and 45, and his grandmother was diagnosed at 69.

However, the proband’s father – who presumably carries an FH mutation – remains well and without RCC at the age of 54. Additionally, while all families showed a trend towards earlier onset of disease in later generations, two other families included examples where a family member was diagnosed at an older age than a relative from a previous generation. Therefore, although there is clear evidence of genetic anticipation in HLRCC, it is not a fully penetrant phenomenon.

Genetic anticipation is commonly seen in neurodegenerative disorders and greater disease severity is caused by increased expansions of triplet repeats in each generation (Trottier et al., 1994). However, the mechanism responsible for genetic anticipation outside of triplet-repeat disorders is less clear. Martinez-Delgado et al. (2011) showed that women with hereditary breast cancers had shortened telomeres due to BRCA mutations, which likely occurred during DNA transmission from parent to child.

Telomeres protect the end of chromosomes from genomic rearrangement, and shortened telomeres predispose to cancer (Willeit et al., 2010). Telomeres shortening has also been reported to be the cause of genetic anticipation in Li-Fraumeni syndrome and dyskeratosis congenita (Tabori et al., 2007, Vulliamy et al., 2004), meaning this may be the mechanism causing genetic anticipation in HLRCC. However, neither triplet repeat expansion nor telomere shortening cause genetic anticipation in Lynch syndrome (Seguí et al., 2013), meaning that there is at least one additional mechanism to be discovered.

Improved screening or better awareness of symptoms, especially if an individual is known to be at risk, could explain the genetic anticipation seen in some conditions. However, in the four families under the care of the authors of this study, most patients presented with advanced RCC and died within a few years of their diagnosis. This suggests that genetic anticipation seen in HLRCC is not caused by earlier diagnosis, but that patients in later generations really are developing symptoms at a younger age.  In this case, genetic anticipation makes it difficult to design a screening programme that is appropriate for all patients. However, due to the young age of some HLRCC patients – RCC has been reported in an 11 year old child with HLRCC (Alrashdi et al., 2010) – and the aggressive nature of the disease, the authors recommend commencing kidney screening at the age of 10.

This is a small study analysing 11 HLRCC families, and cannot rule out birth cohort or environmental effects as causes of earlier symptom development in younger patients. More information is required before genetic anticipation in HLRCC is fully understood. Data collected by the Cancer in our Genes International Patient Databank will help answer this question though, and may shed light on whether some mutations cause more extreme genetic anticipation than others. Indeed, retrospective analysis of the German Familial Pancreatic Cancer patient registry showed that there is genetic anticipation in hereditary pancreatic cancer (Schneider et al., 2011). Thus, the CGIP Databank may also reveal any genetic anticipation in BHD, VHL or SDHB.

  • Alrashdi I, Levine S, Paterson J, Saxena R, Patel SR, Depani S, Hargrave DR, Pritchard-Jones K, & Hodgson SV (2010). Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient. Familial cancer, 9 (2), 239-43 PMID: 19967458
  • Dagan E, & Gershoni-Baruch R (2002). Anticipation in hereditary breast cancer. Clinical genetics, 62 (2), 147-50 PMID: 12220452
  • Martinez-Borges AR, Petty JK, Hurt G, Stribling JT, Press JZ, & Castellino SM (2009). Familial small cell carcinoma of the ovary. Pediatric blood & cancer, 53 (7), 1334-6 PMID: 19621450
  • Martinez-Delgado B, Yanowsky K, Inglada-Perez L, Domingo S, Urioste M, Osorio A, & Benitez J (2011). Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS genetics, 7 (7) PMID: 21829373
  • Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, & Bartsch DK (2011). German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Familial cancer, 10 (2), 323-30 PMID: 21207249
  • Seguí N, Pineda M, Guinó E, Borràs E, Navarro M, Bellido F, Moreno V, Lázaro C, Blanco I, Capellá G, & Valle L (2013). Telomere length and genetic anticipation in Lynch syndrome. PloS one, 8 (4) PMID: 23637804
  • Tabori U, Nanda S, Druker H, Lees J, & Malkin D (2007). Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer research, 67 (4), 1415-8 PMID: 17308077
  • Trottier Y, Biancalana V, & Mandel JL (1994). Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. Journal of medical genetics, 31 (5), 377-82 PMID: 8064815
  • Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, & Dokal I (2004). Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature genetics, 36 (5), 447-9 PMID: 15098033
  • Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstätter A, Kronenberg F, & Kiechl S (2010). Telomere length and risk of incident cancer and cancer mortality. JAMA : the journal of the American Medical Association, 304 (1), 69-75 PMID: 20606151
  • Wong MH, Tan CS, Lee SC, Yong Y, Ooi AS, Ngeow J, & Tan MH (2014). Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC). Familial cancer PMID: 24526232


3 thoughts on “Evidence of genetic anticipation in HLRCC

  1. Thank you for the excellent summary of our article. I am glad that this was of interest, and agree that our observations drawn from a systematic review need to be validated independently, ideally from a prospective registry.

Leave a Reply